PrairieGold Venture Partners
VC Fund
Sioux Falls, United States
PrairieGold Venture Partners is an early-stage venture capital company that invests in life sciences and green technology companies.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries PrairieGold Venture Partners invests in
Health CareBiotechnologySoftwareHealth DiagnosticsFuel
Stages PrairieGold Venture Partners invests in
Series BSeries ASeries CFunding RoundSeries D
Countries PrairieGold Venture Partners invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Mike Jerstad
|
|||
|
Paul Batcheller
|
|||
|
Susan Simko
|
|||
Investment Focus
Industry
- Health Care 4 (20%)
- Biotechnology 3 (15%)
- Software 2 (10%)
- Health Diagnostics 2 (10%)
- Fuel 1 (5%)
Stage
- Series B 7 (35%)
- Series A 4 (20%)
- Series C 4 (20%)
- Funding Round 2 (10%)
- Series D 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Mike Jerstad
Partner
|
Partner | Total investments: 13 | Find email | |
|
Paul Batcheller
Partner
|
Partner | Total investments: 7 | Find email | |
|
Susan Simko
CFO
|
CFO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Virtual Incision
|
Virtual Incision is reimagining robotic support for minimally invasive (MIS) procedures with simple innovations offering mobility, flexibility, and accessibility to provide MIS options to more patients. It has develops the MIRA® (Miniaturized In vivo Robotic Assistant) Platform, a first-of-its-kind miniaturized surgical robotic support device,focusing first on colon resection, with follow-on specialty robots for additional potential applications. | $30M / Series C / Sep 19, 2023 | |
|
Virtual Incision
|
Virtual Incision is reimagining robotic support for minimally invasive (MIS) procedures with simple innovations offering mobility, flexibility, and accessibility to provide MIS options to more patients. It has develops the MIRA® (Miniaturized In vivo Robotic Assistant) Platform, a first-of-its-kind miniaturized surgical robotic support device,focusing first on colon resection, with follow-on specialty robots for additional potential applications. | $20M / Series B / Jan 08, 2020 | |
|
Virtual Incision
|
Virtual Incision is reimagining robotic support for minimally invasive (MIS) procedures with simple innovations offering mobility, flexibility, and accessibility to provide MIS options to more patients. It has develops the MIRA® (Miniaturized In vivo Robotic Assistant) Platform, a first-of-its-kind miniaturized surgical robotic support device,focusing first on colon resection, with follow-on specialty robots for additional potential applications. | $18M / Series B / Dec 12, 2017 | |
|
Virtual Incision
|
Virtual Incision is reimagining robotic support for minimally invasive (MIS) procedures with simple innovations offering mobility, flexibility, and accessibility to provide MIS options to more patients. It has develops the MIRA® (Miniaturized In vivo Robotic Assistant) Platform, a first-of-its-kind miniaturized surgical robotic support device,focusing first on colon resection, with follow-on specialty robots for additional potential applications. | $11.2M / Aug 06, 2015 | |
Lineagen
|
Lineagen is a provider of diagnostic and healthcare services focused on complex diseases for which an individual's genetic profiles contribute strongly to their susceptibility. Lineagen is committed to improving outcomes for those affected by autism and other complex diseases, for which effective early diagnosis and intervention can have asignificant positive impact. The company's comprehensive genetic testing and support/counseling service are initially designed to enable early evaluation of children at risk for disorders of childhood development, including autism spectrum disorders (ASDs). Founded in 2002, Lineagen's commercial strategy represents the culmination of significant proprietary research into genetic causes and diagnostic pathways of key complex diseases, including autism, MS, and COPD. One of the company's core research competitive advantages is its access through the University of Utah to the Utah Population Database, an unmatched biomarker discovery research platform that has been used to help the University identify more disease-related genes than any other institution in the world. | $12.2M / Series C / Jan 26, 2015 | |
Agrivida
|
Agrivida is an agricultural biotechnology company that creates renewable, biomass-based alternative fuels, and raw materials. It develops corn varieties that are optimized for producing ethanol from corn stover. Ethanol is a clean-burning, renewable fuel that can be used as a gasoline additive or a gasoline replacement.It was founded in 2002 andis based in Cambridge, Massachusetts. | $12.3M / Series D / Jan 05, 2015 | |
|
Lineagen
|
Lineagen is a provider of diagnostic and healthcare services focused on complex diseases for which an individual's genetic profiles contribute strongly to their susceptibility. Lineagen is committed to improving outcomes for those affected by autism and other complex diseases, for which effective early diagnosis and intervention can have asignificant positive impact. The company's comprehensive genetic testing and support/counseling service are initially designed to enable early evaluation of children at risk for disorders of childhood development, including autism spectrum disorders (ASDs). Founded in 2002, Lineagen's commercial strategy represents the culmination of significant proprietary research into genetic causes and diagnostic pathways of key complex diseases, including autism, MS, and COPD. One of the company's core research competitive advantages is its access through the University of Utah to the Utah Population Database, an unmatched biomarker discovery research platform that has been used to help the University identify more disease-related genes than any other institution in the world. | $3.5M / Series C / Dec 18, 2013 | |
Chronix Biomedical
|
Chronix Biomedical is pioneering a breakthrough approach to the diagnosis and management of chronic diseases and cancer. It has developed proprietary technology that measures and categorizes circulating nucleic acids, DNA sequences circulating in the blood that are associated with specific changes in disease and health status. Chronix plans tocollaborate with a variety of partners to develop and market its DNA-based assays that have the potential to transform the management of a broad range of cancers and other conditions. Chronix is headquartered in San Jose, California and has research facilities in Germany. | $1.4M / Oct 31, 2012 | |
|
Agrivida
|
Agrivida is an agricultural biotechnology company that creates renewable, biomass-based alternative fuels, and raw materials. It develops corn varieties that are optimized for producing ethanol from corn stover. Ethanol is a clean-burning, renewable fuel that can be used as a gasoline additive or a gasoline replacement.It was founded in 2002 andis based in Cambridge, Massachusetts. | $15M / Series C / Sep 12, 2012 | |
ZeaChem
|
ZeaChem will change the world by creating high margin and sustainable alternatives to petroleum-based fuels and chemicals. Able to use wood chips, wheat straw, corn stover, or grasses to make a range of drop-in products for the $1T+ chemicals and fuels markets, ZeaChem can profit today without any subsidies and is competitive with $50 per barreloil. ZeaChem’s advantage centers around its fermentation process which converts 100% of the carbon in the sugars into end products, delivering unmatched yields | $19M / Series C / Feb 14, 2012 | |
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Energy Investors
25,111 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
Health Care VC Funds
32,370 investors
FAQ
What does PrairieGold Venture Partners invest in?
PrairieGold Venture Partners invests primarily in Health Care, Biotechnology and Software startups, most often at Series B and Series A stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact PrairieGold Venture Partners?
Public channels for PrairieGold Venture Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at PrairieGold Venture Partners?
The team at PrairieGold Venture Partners includes Mike Jerstad (Partner), Paul Batcheller (Partner) and Susan Simko (CFO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
